Thermo Fisher Scientific TMO Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Consolidated revenues by Business | ||||||
| Analytical Instruments | $1.72B-22.5% | $2.22B+17.0% | $1.89B+9.5% | $1.73B+0.6% | $1.72B-21.4% | |
| Laboratory Products and Biopharma Services | $6.04B-5.4% | $6.38B+6.9% | $5.97B-0.4% | $6B+6.3% | $5.64B-5.0% | |
| Life Sciences Solutions | $2.64B-10.5% | $2.95B+13.8% | $2.59B+3.6% | $2.5B+6.7% | $2.34B-10.1% | |
| Specialty Diagnostics | $1.14B-6.4% | $1.22B+3.9% | $1.17B+3.5% | $1.13B-1.2% | $1.15B-0.8% | |
| Cost of revenues by Business | ||||||
| Analytical Instruments | $876M-23.0% | $1.14B+16.6% | $975M+8.0% | $903M+8.1% | $835M-16.7% | |
| Laboratory Products and Biopharma Services | $4.76B-2.5% | $4.88B+5.6% | $4.62B-1.6% | $4.7B+6.5% | $4.41B-2.6% | |
| Life Sciences Solutions | $1B-15.4% | $1.19B+23.5% | $961M+3.8% | $926M+8.3% | $855M-12.1% | |
| Specialty Diagnostics | $657M-8.4% | $717M+5.1% | $682M+6.6% | $640M-5.7% | $679M-1.0% | |
| Operating Income (Loss) by Business | ||||||
| Analytical Instruments | $355M-39.1% | $583M+35.9% | $429M+32.0% | $325M-18.5% | $399M-40.1% | |
| Laboratory Products and Biopharma Services | $778M-15.9% | $925M+6.6% | $868M+5.1% | $826M+13.0% | $731M-11.7% | |
| Life Sciences Solutions | $954M-8.8% | $1.05B+8.1% | $968M+5.2% | $920M+10.3% | $834M-12.4% | |
| Specialty Diagnostics | $313M-3.4% | $324M+0.9% | $321M+4.6% | $307M+1.0% | $304M+11.4% | |
| Other segment items by Business | ||||||
| Analytical Instruments | $34M-20.9% | $43M+10.3% | $39M+8.3% | $36M+9.1% | $33M-37.7% | |
| Laboratory Products and Biopharma Services | -$110M-83.3% | -$60M+48.3% | -$116M+18.9% | -$143M-38.8% | -$103M-348% | |
| Life Sciences Solutions | $50M-20.6% | $63M+18.9% | $53M+1.9% | $52M+15.6% | $45M-33.8% | |
| Specialty Diagnostics | -$49M-14.0% | -$43M+6.5% | -$46M-7.0% | -$43M+15.7% | -$51M-75.9% | |
| Selling, general and administrative expenses by Business | ||||||
| Analytical Instruments | $313M+2.6% | $305M-0.7% | $307M-3.8% | $319M+1.9% | $313M-1.3% | |
| Laboratory Products and Biopharma Services | $597M-3.6% | $619M+6.4% | $582M-3.5% | $603M+2.6% | $588M0.0% | |
| Life Sciences Solutions | $496M-2.0% | $506M+7.7% | $470M+0.4% | $468M0.0% | $468M+1.1% | |
| Specialty Diagnostics | $177M-1.1% | $179M+2.3% | $175M-4.4% | $183M+7.0% | $171M-4.5% | |
| Segment assets by Business | ||||||
| Analytical Instruments | $3.1B-2.1% | $3.17B-0.6% | $3.19B— | —— | $2.99B+1.4% | |
| Laboratory Products and Biopharma Services | $6.92B+6.7% | $6.49B-4.1% | $6.76B— | —— | $6.47B+5.2% | |
| Life Sciences Solutions | $3.49B+1.3% | $3.45B-3.0% | $3.55B— | —— | $3.02B+1.2% | |
| Specialty Diagnostics | $1.33B+0.7% | $1.32B+1.2% | $1.31B— | —— | $1.3B+6.6% | |
| Research and development expenses by Business | ||||||
| Analytical Instruments | $139M-5.4% | $147M+2.1% | $144M-0.7% | $145M+5.8% | $137M-6.2% | |
| Laboratory Products and Biopharma Services | $15M0.0% | $15M+7.1% | $14M0.0% | $14M+7.7% | $13M-18.8% | |
| Life Sciences Solutions | $131M-9.7% | $145M+6.6% | $136M+2.3% | $133M-4.3% | $139M-6.1% | |
| Specialty Diagnostics | $44M0.0% | $44M+4.8% | $42M-10.6% | $47M+4.4% | $45M-6.3% | |
| Restructuring and other costs by Business | ||||||
| Analytical Instruments | $4M-69.2% | $13M-75.9% | $54M— | —— | —— | |
| Laboratory Products and Biopharma Services | $33M+313% | $8M-79.5% | $39M— | —— | —— | |
| Life Sciences Solutions | $9M-59.1% | $22M-71.8% | $78M— | —— | —— | |
| Purchases of property, plant and equipment by Business | ||||||
| Analytical Instruments | $36M-26.5% | $49M+172% | $18M+38.5% | $13M-70.5% | $44M+41.9% | |
| Laboratory Products and Biopharma Services | $259M-13.1% | $298M+0.3% | $297M+44.9% | $205M0.0% | $205M-38.6% | |
| Life Sciences Solutions | $20M-60.8% | $51M+59.4% | $32M+23.1% | $26M-39.5% | $43M-4.4% | |
| Specialty Diagnostics | $35M-2.8% | $36M+5.9% | $34M+36.0% | $25M-24.2% | $33M-28.3% | |
| Depreciation of property, plant and equipment by Business | ||||||
| Analytical Instruments | $26M-7.1% | $28M+7.7% | $26M0.0% | $26M+8.3% | $24M-11.1% | |
| Laboratory Products and Biopharma Services | $186M+12.7% | $165M+43.5% | $115M-24.3% | $152M-11.6% | $172M-8.0% | |
| Life Sciences Solutions | $70M-5.4% | $74M+19.4% | $62M+10.7% | $56M-5.1% | $59M0.0% | |
| Specialty Diagnostics | $24M+4.3% | $23M0.0% | $23M0.0% | $23M+4.5% | $22M-31.3% | |
| Consolidated revenues by Product | ||||||
| Consumables | $4.72B-6.0% | $5.03B+7.4% | $4.68B+1.6% | $4.61B+5.8% | $4.35B-3.6% | |
| Instruments | $1.56B-30.0% | $2.22B+22.6% | $1.81B+10.2% | $1.64B+1.0% | $1.63B-27.7% | |
| Service revenues | $4.73B-4.9% | $4.97B+7.3% | $4.63B+0.6% | $4.61B+5.1% | $4.38B-5.3% | |
| Consolidated revenues by Geography | ||||||
| Asia-Pacific | $1.97B-13.5% | $2.28B+13.1% | $2.01B+4.8% | $1.92B+1.5% | $1.89B-14.1% | |
| Europe | $2.96B-12.2% | $3.37B+12.0% | $3.01B+6.2% | $2.83B+7.9% | $2.62B-9.2% | |
| North America | $5.71B-6.6% | $6.11B+7.4% | $5.69B-0.6% | $5.72B+3.8% | $5.51B-6.0% | |
| Other regions | $372M-19.5% | $462M+11.3% | $415M+8.4% | $383M+13.6% | $337M-23.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Thermo Fisher Scientific break its business down?
- Thermo Fisher Scientific (TMO) reports consolidated revenues by business across 4 parts — Analytical Instruments, Laboratory Products and Biopharma Services, Life Sciences Solutions and Specialty Diagnostics. Each is extracted from the segment footnotes and tracked over time.
- Where does Thermo Fisher Scientific's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Thermo Fisher Scientific's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
